These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8639896)

  • 1. Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics.
    Englender T; Lattuada A; Mannucci PM; Sadler JE; Inbal A
    Blood; 1996 Apr; 87(7):2788-94. PubMed ID: 8639896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
    Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
    Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
    Kashiwagi T; Matsushita T; Ito Y; Hirashima K; Sanda N; Fujimori Y; Yamada T; Okumura K; Takagi A; Murate T; Katsumi A; Takamatsu J; Yamamoto K; Naoe T; Kojima T
    Haemophilia; 2008 May; 14(3):556-63. PubMed ID: 18397285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
    Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
    Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.
    Obser T; Ledford-Kraemer M; Oyen F; Brehm MA; Denis CV; Marschalek R; Montgomery RR; Sadler JE; Schneppenheim S; Budde U; Schneppenheim R
    J Thromb Haemost; 2016 Sep; 14(9):1725-35. PubMed ID: 27344059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.
    Dong J; Zhao X; Shi S; Ma Z; Liu M; Wu Q; Ruan C; Dong N
    PLoS One; 2012; 7(3):e33263. PubMed ID: 22479377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.
    Schneppenheim R; Budde U; Obser T; Brassard J; Mainusch K; Ruggeri ZM; Schneppenheim S; Schwaab R; Oldenburg J
    Blood; 2001 Apr; 97(7):2059-66. PubMed ID: 11264172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
    Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
    Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.
    O'Brien LA; Sutherland JJ; Hegadorn C; Benford K; Racz H; Rapson D; Hough C; Lillicrap D
    J Thromb Haemost; 2004 Jul; 2(7):1135-42. PubMed ID: 15219197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
    Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
    Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Leu777Pro and Ile865Thr type IIA von Willebrand disease mutations.
    Lyons SE; Cooney KA; Bockenstedt P; Ginsburg D
    Blood; 1994 Mar; 83(6):1551-7. PubMed ID: 8123844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
    Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
    J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.